Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Open-Label, Active-Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Patients 1 to <12 Years of Age With Influenza Symptoms

NCT06774859 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT06774859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06774859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Open-Label, Active-Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Patients 1 to <12 Years of Age With Influenza Symptoms
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
October 27, 2024
Completion date
May 8, 2025
Enrollment
100 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

influenza